Drug Discovery and Development Solutions for Malaria

Our In Vitro Efficacy Testing Service for malaria accelerates antimalarial drug discovery by providing robust, high-throughput screening of candidate compounds. Utilizing advanced chemiluminescent assays, we quantitatively assess Plasmodium viability, drug response, and key molecular targets such as Tumor Protein P53. We determine Minimum Effective Concentration (MEC) to precisely evaluate compound potency and efficacy, enabling reliable ranking and optimization of leads. Our sensitive and reproducible methods support rapid screening of large compound libraries, delivering actionable data to guide early-stage drug development and facilitate the selection of promising antimalarial agents for further preclinical evaluation.

Ace Therapeutics offers comprehensive in vivo malaria animal model development, supporting drug efficacy, vaccine, and mechanistic studies. Utilizing over 278 validated models across nine species and 50 strains, we provide protozoal infection, genetically engineered, xenograft, mosquito bite-induced, and comorbidity models. Our service includes customized model selection, precise infection protocols, and advanced analytics such as bioluminescence imaging, immunophenotyping, and PK/PD assessment. Rigorous quality control ensures data integrity and regulatory compliance. Partnering with us accelerates malaria research, enabling robust evaluation of novel therapies and interventions in physiologically relevant, translational animal models tailored to your research objectives.

Our PK/PD research service for malaria offers comprehensive analysis of drug absorption, distribution, metabolism, and excretion using advanced analytical techniques such as HPLC, LC-MS, ELISA, and bioassays. We support multiple administration routes and conduct compartmental studies in diverse biological matrices across a range of animal models. This integrated approach delivers robust data on concentration-effect relationships and optimal dosing, facilitating rational dose selection, efficacy optimization, and resistance mitigation. Our expertise and state-of-the-art methodologies accelerate antimalarial drug development, ensuring reliable translational insights that support both preclinical research and clinical advancement for effective malaria therapies.

Ace Therapeutics delivers comprehensive in vivo toxicity assessment services tailored for malaria drug development. Utilizing advanced methodologies and validated animal models, we conduct acute, chronic, organ-specific, and systemic toxicity studies, adhering to international regulatory standards. Our capabilities include automated behavioral tracking, high-throughput clinical chemistry, and digital histopathology, ensuring precise, reproducible data. Specialized endpoints address malaria-specific risks, including hepatic, renal, and immunological toxicities. Rigorous quality control and integrated data management support robust statistical analysis and early safety signal detection. Our service empowers informed decision-making, accelerates regulatory submissions, and ensures the highest safety standards for antimalarial therapeutics.

Ace Therapeutics offers specialized biomarker analysis services for malaria research, utilizing advanced multi-omics approaches—including genomics, transcriptomics, proteomics, and metabolomics—to explore and screen molecular indicators with potential as biomarkers. Our team employs systematic discovery, rigorous screening, and evaluation methodologies across diverse analytical platforms such as immunoassays, mass spectrometry, and flow cytometry. We assess candidate biomarkers by investigating their relevance to malaria pathophysiology, immune response, and metabolic changes. All services focus on preclinical research, emphasizing careful evaluation, reproducibility, and scientific rigor while maintaining objectivity regarding the potential of explored biomarker candidates.